Concepedia

Safety and efficacy of MIM D3 ophthalmic solutions in a randomized placebo controlled Phase 2 clinical trial in patients with dry eye

Karen Meerovitch, Gail Torkildsen, John Lonsdale, Heidi B. Goldfarb, Teresa Lama, Garth Cumberlidge, George W Ousler

Clinical ophthalmology · 2013 · 67 citations · 26 references

DOIFull text

Open access

Abstract

Treatment with topical ophthalmic MIM-D3 demonstrated protection against the effects of a CAE challenge on dry eye signs, reduced patient-reported diary symptoms, with a favorable safety profile.

References

26

The Relationship between Habitual Patient-Reported Symptoms and Clinical Signs among Patients with Dry Eye of Varying Severity

Carolyn G. Begley, Robin L. Chalmers, Linda Abetz et al. · Investigative Ophthalmology & Visual Science · 2003 · 420 citations

Topical Treatment with Nerve Growth Factor for Corneal Neurotrophic Ulcers

Alessandro Lambìase, Paolo Rama, Stefano Bonini et al. · New England Journal of Medicine · 1998 · 414 citations · Full text

Decreased levels of the goblet cell mucin MUC5AC in tears of patients with Sjögren syndrome.

Pablo Argüeso, Mini Balaram, Sandra Spurr-Michaud et al. · PubMed · 2002 · 349 citations

Topical treatment with nerve growth factor for neurotrophic keratitis

Stefano Bonini · Ophthalmology · 2000 · 312 citations

, , +5

A Link between Tear Instability and Hyperosmolarity in Dry Eye

Haixia Liu, Carolyn G. Begley, Minhua Chen et al. · Investigative Ophthalmology & Visual Science · 2009 · 312 citations